Cancer
is
one
of
the
leading
causes
death
worldwide.
Early
cancer
detection
critical
because
it
can
significantly
improve
treatment
outcome
thus
saving
lives,
reducing
suffering,
and
lessening
psychological
economic
burdens.
biomarkers
provide
varied
information
about
cancer,
from
early
malignancy
to
decisions
on
subsequent
monitoring.
A
large
variety
molecular,
histologic,
radiographic,
or
physiological
entities
features
are
amongst
common
types
biomarkers.
Sizeable
recent
methodological
progress
insights
have
promoted
significant
development
in
field
Here
we
an
overview
advancement
knowledge
related
biomolecules
cellular
used
for
detection.
We
examine
data
CAS
Content
Collection,
largest
human-curated
collection
published
scientific
information,
as
well
biomarker
datasets
at
Excelra,
analyze
publication
landscape
research.
also
discuss
evolution
key
concepts,
pipelines,
with
a
particular
focus
pancreatic
liver
cancers,
known
remarkably
difficult
detect
early,
particularly
high
morbidity
mortality.
The
objective
paper
broad
evolving
current
biomarkers,
outline
challenges
evaluate
growth
opportunities,
order
further
efforts
solving
problems
that
remain.
merit
article
stems
extensive,
wide-ranging
coverage
most
up-to-date
scientific
allowing
unique,
unmatched
breadth
analysis
in-depth
insights.
Advanced Therapeutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 3, 2025
Abstract
The
rise
of
antibiotic‐resistant
bacteria,
driven
by
antibiotic
misuse,
is
a
major
global
health
threat.
Addressing
this
issue
requires
understanding
resistance
mechanisms
and
developing
innovative
solutions.
Clustered
Regularly
Interspaced
Short
Palindromic
Repeats
(CRISPR)‐associated
systems
(Cas),
genome‐editing
tool
derived
from
prokaryotic
defense
mechanisms,
offers
precise
targeting
genes.
By
reprogramming
CRISPR‐Cas,
bacteria
can
be
killed
or
resensitized
to
antibiotics
through
plasmid
curing.
However,
clinical
applications
face
challenges,
particularly
in
delivering
CRISPR‐Cas
components
effectively.
Nanotechnology
has
emerged
as
promising
approach
for
targeted
delivery
tissues
cells.
This
paper
explores
the
molecular
resistance,
emphasizing
structure
function
their
mechanisms.
It
highlights
use
nanoparticles
(NPs)
nanoscale
carriers
deliver
components,
reviewing
recent
studies
that
combine
NPs
CRISPR
target
Additionally,
discusses
current
challenges
future
prospects
field,
underscoring
potential
nanotechnology
combat
resistance.
